Mechanism of action:
In this hybrid monoclonal antibody i.e. constant regions of human immunoglobulin and Fab fragments of murine monoclonal antibody gets bind to platelet GP IIb/IIIa receptos leading to blockage of the binding of fibrinogen and von Willebrand factor resulting in inhibition of aggregation.
It is administered intravenously with aspirin and heparin.
Note: After stoppage of therapy platelet function gradually returns to normal.
Therapeutic uses:
It is used for the prevention of cardiac ischemia.
It is also recommended for patients with unstable angina.
Adverse effects:
It may cause bleeding disorders. Thrombocytopenia may also be caused.
No comments:
Post a Comment